Valuation: SurModics

Market Cap 43Cr 37Cr 34Cr 32Cr 61Cr 4.07TCr 62Cr 412.87Cr 160.01Cr 2TCr 160.46Cr 156.98Cr 6.88TCr P/E 2023
-292x
P/E 2024 -47.3x
Enterprise Value 42Cr 37Cr 34Cr 31Cr 60Cr 4TCr 61Cr 406.23Cr 157.43Cr 1.96TCr 157.88Cr 154.45Cr 6.77TCr EV / Sales 2023
3.33x
EV / Sales 2024 4.33x
Free-Float
99.63%
Yield 2023 *
-
Yield 2024 -
1 year 25.87
Extreme 25.87
43
3 years 25.17
Extreme 25.17
43
5 years 16
Extreme 16
62.27
10 years 16
Extreme 16
82.35
Manager TitleAgeSince
Chief Executive Officer 67 19/11/2025
Director of Finance/CFO 53 19/11/2025
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 67 19/11/2025
Director/Board Member 53 19/11/2025
Date Insider Type Main position Quantity % Market Cap.
19/11Issuer sale

Executive/Senior Manager

1,71,148 1.1970%
19/11Issuer sale

Director

62,052 0.4340%
19/11Issuer sale

Director

51,877 0.3628%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%-.--%+46.79%+37.27% 61Cr
+3.49%+2.32%-28.86%-11.02% 16TCr
+5.04%+3.32%-5.77%-4.53% 10TCr
+2.80%+3.33%+1.83%+55.31% 5.61TCr
-1.22%-2.88%+53.69%+49.87% 5.34TCr
+3.39%+4.43%-10.83%-39.65% 4.21TCr
+3.50%+14.35% - - 3.53TCr
+3.47%+3.79%-14.75%-43.91% 2.66TCr
+0.20%+5.53%+65.33%-3.33% 2.58TCr
+2.78%+3.61%-8.42%-0.43% 2.07TCr
Average +2.09%+2.80%+11.00%+4.40% 5.22TCr
Weighted average by Cap. +2.58%+2.00%-3.20%+1.28%

Financials

2023 2024
Net sales 13Cr 12Cr 11Cr 9.92Cr 19Cr 1.26TCr 19Cr 128.09Cr 50Cr 619.1Cr 50Cr 49Cr 2.13TCr 13Cr 11Cr 10Cr 9.43Cr 18Cr 1.2TCr 18Cr 121.8Cr 47Cr 588.72Cr 47Cr 46Cr 2.03TCr
Net income -15.36L -13.42L -12.32L -11.49L -21.79L -15Cr -22.16L -1.48Cr -57.51L -7.17Cr -57.67L -56.42L -25Cr -1.15Cr -1.01Cr -92.61L -86.37L -1.64Cr -109.88Cr -1.66Cr -11Cr -4.32Cr -54Cr -4.33Cr -4.24Cr -185.71Cr
Net Debt -1.21Cr -1.06Cr -97.1L -90.55L -1.72Cr -115.2Cr -1.75Cr -12Cr -4.53Cr -57Cr -4.54Cr -4.44Cr -194.7Cr -68.7L -60.03L -55.12L -51.41L -97.46L -65Cr -99.1L -6.64Cr -2.57Cr -32Cr -2.58Cr -2.52Cr -110.54Cr
Logo SurModics
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Employees
389
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. SRDX Stock